Evercore ISI Group Maintains Outperform on Insmed, Raises Price Target to $170

Benzinga Newsdesk www.benzinga.com Positive 89.2%

Neg 0% Neu 0% Pos 89.2%

Evercore ISI Group analyst Josh Schimmer maintains Insmed (NASDAQ:INSM) with a Outperform and raises the price target from $160 to $170.